We combine large firm expertise with small firm attention. Our clients can expect the best results and the most personal experience.
The Chemours Company is facing a class action lawsuit alleging that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) certain of the Company’s senior executive officers manipulated Free Cash Flow targets as a means to maximize additional cash and stock incentive compensation applicable to executive officers pursuant to the Company’s annual incentive plans and long-term incentive plans; (2) the Company’s accounting practices and procedures, including its internal control over financial reporting, were deficient; and (3) as a result, defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis.
If you incurred a loss on CC common stock purchased between February 10, 2023 and February 28, 2024, this lawsuit is on your behalf. The lawsuit was filed in the United States District Court for the District of Delaware, and our firm is reaching out to investors to discuss their legal rights.
If you wish to act as a representative of the shareholders harmed by this misconduct, you may ask the court to appoint you as lead plaintiff. A lead plaintiff directs the litigation and participates in important decisions, including whether to accept a settlement for the class in the action.
You only have until May 20, 2024 to apply to be lead plaintiff. The court will then evaluate the applicants and choose a lead plaintiff. You are not required to act as a lead plaintiff in order to participate in any recovery.
Enter the following information for this class action case- the deadline is approaching.
See If you Qualify for Monetary Reward
Loss Submission Form